The more gains you seek, the more losses will inadvertently occur along the way. Being so fixated on accomplishing the pre-set goals might make you unaware of the losses that aren't always directly related to the goal.

Single fraction lung SBRT has become my go-to for medically inoperable stage I NSCLC. How about others? #radonc pubmed.ncbi.nlm.nih.gov/34048817/

What a huge impact Omar Mian made on all of us here - can’t wait to see your continued success

And so it begins. This is required reading for all brain tumor docs. Vorasidenib: a new hope or a false promise for patients with low-grade glioma? | Nature Reviews Clinical Oncology nature.com/articles/s4157…

So what's the story for day 2 of Esmo24 ? Keynote A18 shows OS benifit. Pembrolizumab in CTRT for cervix. HR 0.67 ( 0.5 to 0.90 ) 82.6 % vs 74.8 % OS at 36 months . OS Benifit seen across all the stages . This should make it new SOC. 🙂👍@esmo #ESMO2024 LARVOL OncoAlert

This is a big deal. Cancer #cachexia is terrible and significantly impacts quality of life for patients.

All well that ends with OS. HR of 0.67 for Pembrolizumab in Keynote A18 What about Interlace approach? KeynoteA18 vs Interlace or Both ? Interlace not yet published since last esmo23 presentation ?? Susana Banerjee M. Bolton Dr Jérôme BARRIERE, MD. LARVOL OncoAlert #ESMO24

Major congrats to my friend Dr Sofia Rivera on the HypoG-01 just presented at #ESMO2024 Hypofractionation not inferior to conventional fractionation for #BreastCancer with nodal RT. ✅Similar toxicity ✅Similar efficacy (BCSM OS LRFS DMFS) 3 weeks is the way to go!

#ESMO24 Lung mini-orals🔥 Randomised ph II trial of inhaled corticosteroids in stage III NSCLC treated with cCRT, to reduce radiation pneumonitis: - 292pts - 15% reduction in RP - no long-term steroid tox No need for ph III, could do tomorrow #ESMOAmbassadors #ESMO24 ESMO - Eur. Oncology

Also found this to be a very notable finding from ADRIATIC & thought the same thing.

Improvements in radiation using IMRT translated into less pneumonitis for locally-advanced NSCLC in NRG Oncology-RTOG 0617 compared to 3D-CRT. Planning should minimize the heart V40Gy and lung V20Gy, as the lung V5Gy had no long-term impact on outcome. ja.ma/3XvFTN7

Unresectable HCC (median tumor diameter 10cm, 60% MVI) treated w IO+SBRT (N=63): -46% achieved complete response, much higher than prior trials of IO alone: atezo/bev (CR 5.5% IMBRAVE150) & STRIDE (3.3% CR) -CR associated w better OS (3yr 76% vs. 28%)! jamanetwork.com/journals/jamao…

Proven! Can we please include #radiotherapy in the BCLC GROUP guidelines!🙏🏻

☢️💊💉Trimodality therapy offers hope for recurrent T1 bladder cancer after BCG failure! ✅ 3-year freedom from cystectomy: 88% ✅ 3-year OS: 69% ✅Distant metastasis at 3 years: 12% An alternative to radical cystectomy, but safety monitoring is key. #BladderCancer #Oncology

The lack of understanding that #radonc should have a routine role in treating #HCC is one of the largest fails in oncology

In patients with locally advanced hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) combined with sorafenib improved progression-free survival and showed a clinically important improvement in overall survival compared to sorafenib alone. ja.ma/3VKXCQl

All these data tell the same story: #SBRT should be the preferred treatment for larger tumours for medically inoperable patients. Now the debate(s) come down to: 1. Which is better for pts (onc control, QOL) for small accessible tumours needing Rx: SBRT or RFA? 2. RN vs SBRT

Bommireddy et al. Samuel Chao Samuel Chao reported on a predictive model for radiation necrosis after SF-SRS for brain metastases, identifying risk factors including tumor size, histology, hemorrhage, and dosimetry across four groups. #JNO Read more:link.springer.com/article/10.100…

Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer: The TAUTEM Randomized Clinical Trial ⁦JAMA Surgery⁩ jamanetwork.com/journals/jamas…

RT for massive HCC. In series (n=156) w median tumor size 12.9 cm, local control w RT (+/- opt'l TACE) = 86%. RT dose modest (4Gy x 6-10 fx): HCC is radiosensitive. Recall in RTOG 1112, med size 7.8 cm. IMO among local HCC tx, RT/SBRT has strongest evidence for larger tumors.